Welcome to the international HTA database

Showing [16733 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Agency for Care Effectiveness (ACE)	Review of cancer drugs for treating early or advanced HER2-positive breast cancer
2022	Health Information and Quality Authority (HIQA)	Descriptive analysis of COVID-19 epidemiological indicators and associated contextual factors in European countries
2022	Agency for Care Effectiveness (ACE)	Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2022	Agency for Care Effectiveness (ACE)	Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Pegcetacoplan (paroxysmal nocturnal haemoglobinuria, pretreated patients)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Migalastat (new therapeutic indication: Fabry disease, 12 to < 16 years)]
2022	Agency for Care Effectiveness (ACE)	Daratumumab-based regimens for newly diagnosed multiple myeloma
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Microwave ablation for liver tumours
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Odevixibat (progressive familial intrahepatic cholestasis)]
2022	Agency for Care Effectiveness (ACE)	Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Hepatic and portal vein embolization prior to major hepatectomy
2022	Agency for Care Effectiveness (ACE)	Review of cancer drugs for chronic lymphocytic leukaemia
2022	Agency for Care Effectiveness (ACE)	Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer
2022	Norwegian Institute of Public Health (NIPH)	Molecular tests for detection of PIK3CA mutations in men and postmenopausal women with HR+/HER2–, locally advanced or metastatic breast cancer: a health technology assessment
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tafasitamab (diffuse large B-cell lymphoma (DLBCL), combination with lenalidomide)]
2022	Norwegian Institute of Public Health (NIPH)	Zephyr® valves system in the treatment of emphysema: a single technology assessment
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Vosoritide (achondroplasia, ≥ 2 years)]
2022	Agency for Care Effectiveness (ACE)	Cooral System for the prevention of oral mucositis
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Breast cancer risk assessment tools
2022	Agency for Care Effectiveness (ACE)	Magnetic resonance image guided radiation therapy for patients with cancer
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Testosterone reference ranges for gender diverse individuals
2022	Agency for Care Effectiveness (ACE)	Robot-assisted endovascular intervention systems for coronary artery disease and other vascular diseases
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Structured screening questionnaires for alcohol misuse/alcohol use disorders
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Home-based oral nutritional supplements in cancer patients who require modification of the usual ordinary diet due to mucositis]
2022	Agency for Care Effectiveness (ACE)	Nicotine replacement therapies to aid smoking cessation
2022	Agency for Care Effectiveness (ACE)	Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease
2022	Agency for Care Effectiveness (ACE)	Sodium zirconium cyclosilicate for treating hyperkalaemia
2022	Agency for Care Effectiveness (ACE)	Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Clinical utility of inpatient fall risk assessment
2022	Agency for Care Effectiveness (ACE)	Acarbose for treating type 2 diabetes mellitus
2022	Agency for Care Effectiveness (ACE)	Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis
2022	Norwegian Institute of Public Health (NIPH)	Tests for the detection of NTRK gene fusions in patients with locally advanced or metastatic solid tumours
2022	Agency for Care Effectiveness (ACE)	Recombinant blood products for prophylaxis and management of haemophilia A and B
2022	Austrian Institute for Health Technology Assessment (AIHTA)	CAR-T cell-therapies in development, update 2022
2022	Agency for Care Effectiveness (ACE)	GLP-1 receptor agonist injections for treating type 2 diabetes mellitus
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries
2022	NIHR Health Technology Assessment programme	Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Quality improvement strategies in trauma care: review and proposal of 31 novel quality indicators
2022	NIHR Health Services and Delivery Research programme	Components of interventions to reduce restrictive practices with children and young people in institutional settings: the Contrast systematic mapping review
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Achieving safe surgery after COVID-19 vaccination
2022	NIHR Health Services and Delivery Research programme	Assessment and management pathways of older adults with mild cognitive impairment: descriptive review and critical interpretive synthesis
2022	Health Information and Quality Authority (HIQA)	Health technology assessment of metabolic surgery for the treatment of comorbid type 2 diabetes and obesity
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Impact of COVID-19, gender, race, specialty and seniority on mental health during surgical training: an international study
2022	Institute for Clinical and Economic Review (ICER)	Betibeglogene autotemcel for beta thalassemia: effectiveness and value
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Mesh versus non-mesh repair of groin hernias: a rapid review
2022	Institute for Clinical and Economic Review (ICER)	Special assessment of outpatient treatments for COVID-19
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Update: guidelines on the preoperative diagnostic workup for COVID-19
2022	Institute for Clinical and Economic Review (ICER)	Tirzepatide for type 2 diabetes
2022	Malaysian Health Technology Assessment (MaHTAS)	Tertiary care virtual online consultation between doctor and patient
2022	Adelaide Health Technology Assessment (AHTA)	Whole genome sequencing for the diagnosis of mitochondrial disease
2022	NIHR Health Technology Assessment programme	Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT
2022	Adelaide Health Technology Assessment (AHTA)	Review of different minimally invasive therapeutic approaches for the management of patients with benign prostatic hyperplasia
2022	Ontario Health	Transcatheter valve-in-valve implantation for degenerated mitral or tricuspid bioprosthetic valves: a health technology assessment
2022	Ontario Health	Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Adalimumab for the treatment of adults with non-infectious uveitis
2022	Ontario Health	Genetic testing for familial hypercholesterolemia
2022	NIHR Health Technology Assessment programme	One-session treatment compared with multisession CBT in children aged 7–16 years with specific phobias: the ASPECT non-inferiority RCT
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Adalimumab for the treatment of pediatric populations with non-infectious uveitis
2022	Ontario Health	Pre-surgical nasal decolonization of staphylococcus aureus
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Treatments for extreme nausea and vomiting in pregnancy (hyperemesis gravidarum)]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Long COVID care pathways and structures: an updated scoping review
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Stakeholders' perspectives of mobile x-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study
2022	NIHR Health Technology Assessment programme	Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Residents' perspectives of mobile X-ray services in support of healthcare-in-place in residential aged care facilities: a qualitative study.
2022	NIHR Health Services and Delivery Research programme	Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	The utilization and national variation of plain x-ray services by Australian residents of long-term care facilities
2021	Scottish Medicines Consortium (SMC)	Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance on protective measures for vulnerable groups in the context of COVID-19
2021	National Institute for Health and Care Excellence (NICE)	Crizanlizumab for preventing sickle cell crises in sickle cell disease. NICE technology appraisal guidance 743
2021	Scottish Medicines Consortium (SMC)	Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021	Health Technology Wales (HTW)	Strategies for Relatives (START) intervention to improve the mental health of carers of people with dementia
2021	Health Information and Quality Authority (HIQA)	Rolling summary of the evidence in relation to the Omicron (B.1.1.529) variant
2021	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating moderate rheumatoid arthritis. NICE technology appraisal guidance 744
2021	NIHR Health Technology Assessment programme	A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2021	NIHR Health Technology Assessment programme	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs
2021	Belgian Health Care Knowledge Centre (KCE)	Remote monitoring of patients with cardiovascular implantable electronic devices: a health technology assessment (update of the KCE Report 136)
2021	Health Information and Quality Authority (HIQA)	Use of respirator masks by persons who are at higher risk from COVID-19
2021	National Institute for Health and Care Excellence (NICE)	NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal). NICE technology appraisal guidance 745
2021	Health Council of the Netherlands Gezondheidsraad (GR)	[Influenza vaccination: review of indications]
2021	Health Information and Quality Authority (HIQA)	Rapid review of public health guidance for residential care facilities in the context of COVID-19
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. NICE technology appraisal guidance 746
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Long COVID care pathways: a systematic review
2021	WorkSafeBC	Causal association between care aide work and the development of carpal tunnel syndrome (CTS)
2021	National Institute for Health and Care Excellence (NICE)	Nintedanib for treating progressive fibrosing interstitial lung diseases. NICE technology appraisal guidance 747
2021	Center for Drug Evaluation (CDE)	Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Autologous hematopoietic cell transplant for patients with multiple sclerosis
2021	WorkSafeBC	Acupuncture or massage therapy as treatment for occipital neuralgia
2021	National Institute for Health and Care Excellence (NICE)	Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders. NICE technology appraisal guidance 748
2021	Adelaide Health Technology Assessment (AHTA)	Guidelines for preparing assessments for the Medical Services Advisory Committee. Version 1.0
2021	Center for Drug Evaluation (CDE)	Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study
2021	National Institute for Health and Care Excellence (NICE)	Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal). NICE technology appraisal guidance 749
2021	Health Technology Wales (HTW)	Oscillating positive expiratory pressure devices for airway clearance in chronic hypersecretory lung conditions
2021	Adelaide Health Technology Assessment (AHTA)	Immunoglobulin for chronic inflammatory demyelinating polyneuropathy
2021	National Institute for Health and Care Excellence (NICE)	Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 750
2021	NIHR Health Technology Assessment programme	Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review
2021	Adelaide Health Technology Assessment (AHTA)	Genomic testing for the diagnosis of heritable cardiomyopathies
2021	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating severe asthma with type 2 inflammation. NICE technology appraisal guidance 751
2021	National Institute for Health and Care Excellence (NICE)	Belimumab for treating active autoantibody-positive systemic lupus erythematosus. NICE technology appraisal guidance 752
2021	National Institute for Health and Care Excellence (NICE)	Cenobamate for treating focal onset seizures in epilepsy. NICE technology appraisal guidance 753